{"id":667731,"date":"2023-09-13T20:38:01","date_gmt":"2023-09-13T20:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=667731"},"modified":"2023-09-13T20:38:01","modified_gmt":"2023-09-13T20:38:01","slug":"acute-pyelonephritis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-takeda-novo-nordisk","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-pyelonephritis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-takeda-novo-nordisk_667731.html","title":{"rendered":"Acute Pyelonephritis Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies &#8211; Takeda, Novo Nordisk"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acute Pyelonephritis Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies - Takeda, Novo Nordisk \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Acute Pyelonephritis Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies - Takeda, Novo Nordisk \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Acute Pyelonephritis, historical and forecasted epidemiology as well as the Acute Pyelonephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-pyelonephritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>&#8221; report delivers an in-depth understanding of the Acute Pyelonephritis, historical and forecasted epidemiology as well as the Acute Pyelonephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Highlights for Acute Pyelonephritis Market&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key companies working in Anti the hypertension market include Takeda, Novo Nordisk&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key therapies in the Anti- hypertension market include Daratumumab, OBIZUR, and many others&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Market Size for Anti- Hypertension market is expected to be USD XX Million by 2032.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The CAGR for Anti- Hypertension market is expected to be XX%&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Acute Pyelonephritis Overview&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Acute Pyelonephritis is a disorder of rare entity, resulting in spontaneous bleeding in individuals with no history of bleeding disorders. It is believed to be caused by spontaneous inhibition of clotting factor VIII by autoantibodies and is usually associated with other autoimmune conditions.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/90f43cd91130b18b6767d4a6deeeb7b8.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Acute Pyelonephritis Epidemiological Facts&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Its incidence is approximately 1.5 cases\/million\/year The distribution is bimodal with a first-period occurrence between 20 and 30 years old, which mainly corresponds to women who develop this disorder in the postpartum, and a second peak between 68 and 80 years old, corresponding to the majority of patients, with no sex difference.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">An underlying medical condition can be identified in up to 50% of patients, including cancer either solid or hematologic; autoimmune diseases such as rheumatoid arthritis, Sj&ouml;gren syndrome, or bullous pemphigoid; administration of drugs and pregnancy. However, AHA can also emerge in elderly people without any risk factors.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The overall mortality rate in AHA is varies from 20% to 70% depending on the series, attributed to the underlying disorder in about 50% of the cases, infections (5-15%) and major bleeding episodes (4%)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The reason for this loss of tolerance to self-factors is still unclear. There may be different involved mechanisms, such as the presence of certain gene polymorphisms (e.g., HLA, CTLA4) and\/or autoreactive CD4+ T lymphocytes<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-pyelonephritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Acute Pyelonephritis Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Report Covers the Acute Pyelonephritis Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Acute Pyelonephritis Prevalent case&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Acute Pyelonephritis&nbsp; diagnosed cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Acute Pyelonephritis Treatment Case&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Acquired Hemophilia incident cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Acute Pyelonephritis Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Acute Pyelonephritis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Acute Pyelonephritis market trends by analyzing the impact of current Acute Pyelonephritis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">This segment gives a thorough detail of Acute Pyelonephritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Acute Pyelonephritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">According to DelveInsight, the Acute Pyelonephritis market in 7MM is expected to witness a major change in the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Companies Working in the Acute Pyelonephritis Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Takeda&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novo Nordisk&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Acute Pyelonephritis Therapies Covered and Analyzed in the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Daratumumab&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">OBIZUR<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-pyelonephritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies and Emerging Therapies in the Acute Pyelonephritis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Acute Pyelonephritis Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Executive Summary of Acute Pyelonephritis &nbsp; &nbsp; &#8211;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Acute Pyelonephritis Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Acute Pyelonephritis Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-pyelonephritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Acute Pyelonephritis Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acute-pyelonephritis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-takeda-novo-nordisk\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acute-pyelonephritis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-takeda-novo-nordisk\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Acute Pyelonephritis, historical and forecasted epidemiology as well as the Acute Pyelonephritis market trends in the United States, EU5 (Germany, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acute-pyelonephritis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-takeda-novo-nordisk_667731.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-667731","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=667731"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667731\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=667731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=667731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=667731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}